Company Overview and News

Syndax: One Step Backward, Two Forward?

2018-05-23 seekingalpha
Today, we look at a small biotech called Syndax Pharmaceuticals whose stock fell 25% last week on a setback in a trial.

Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Time?

2018-05-21 seekingalpha
Syndax Pharmaceuticals reports that the entire NSCLC population didn't do well with its entinostat combo, however a subpopulation with high levels of monocytes performed much better.

Syndax Pharmaceuticals: What Investors Can Expect From This Potential Grower?

2018-05-18 seekingalpha
Syndax is powering an enriched pipeline of highly promising cancer therapeutics. Entinostat is being investigated in the phase 3 (E2112) trial for a highly difficult-to-treat breast cancer.

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

2018-05-18 seekingalpha
Ultragenyx (NASDAQ:RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; and another approval of borosumab (Crysvita) in April - which also happened. We also liked its cash position, both then and now, and its sale of a Rare Disease Priority Review voucher for $130mn.

Abstracts Unveiled Ahead of ASCO, One Study Pits Novartis and Gilead CAR-T Therapies Head-to-Head

2018-05-17 biospace
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much. BioSpace looks at a handful of the abstract reports.

Eli Lilly Had Good Reason To Spend $1.6B On Armo

2018-05-16 seekingalpha
Last week Eli Lilly (LLY) spent $1.6 billion on to acquire Armo BioSciences (ARMO) at a 66% premium to its previous closing price.

SNDX / Syndax Pharmaceuticals, Inc. 10-Q (Quarterly Report)

sndx-10q_20180331.htm UNITED STATES

Syndax Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-09 seekingalpha
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2018 Q1 earnings call.

Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2018 Results Earnings Conference Call May 8, 2018 4:30 PM ET

BRIEF-Syndax Pharmaceuticals Reports Q1 Loss Per Share $0.79

2018-05-08 reuters

SNDX / Syndax Pharmaceuticals, Inc. 8-K (Current Report)


Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

2018-04-17 247wallst
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates. Shares of Merck & Co. Inc. (NYSE: MRK) saw an increase in value while shares rival drug maker Bristol-Myers Squibb Co. (NYSE: BMY) traded lower after lung cancer study results were presented at the American Association for Cancer Research annual meeting.

SNDX / Syndax Pharmaceuticals, Inc. DEF 14A


SNDX / Syndax Pharmaceuticals, Inc. DEFA14A


Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 87164F105